GlobeNewsWire · ALT · November 5, 2026

Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

Get the app for more

Explore stock news, insights and company research.